Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Company Logo Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2020-2024" report has been added to ...

The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide while reinforcing its commitment to innovation. The acquisition ...

Royalty Pharma plc (NASDAQ:RPRX), a leading funder of innovation across the biopharmaceutical industry with a market capitalization of $19.25 billion and an impressive 99% gross profit margin ...

As we hit the middle of the year, large-scale pharmaceutical acquisitions are well underway. Patterns we have looked into in previous entries continue including the availability of huge amounts of ...

Biotechnology startups historically have relied on top pharmaceutical companies to make acquisition bids. Now a new class of buyers is emerging. Smaller drugmakers increasingly are joining the ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition ... small and mid-cap biotechnology companies to ...

The Japanese pharmaceutical company Taiho Pharmaceutical ... collaborating to design new ADC drugs since late 2023, and the acquisition further solidifies their relationship.

As major pharmaceutical companies began pursuing acquisitions, investor interest surged in late 2023 and early 2024. However, the momentum soon faded, leading to a stagnation in biotech stocks.

The introduction of COVID-19 vaccinations in 2020 caused the biotech industry to soar to prominence. As Big Pharma started investing in acquisitions, investor interest increased in late 2023 and ...